LogicBio Therapeutics (OTCMKTS:LOGC – Get Free Report) is expected to be posting its Q2 2026 resultson Thursday, August 6th. Analysts expect the company to announce earnings of ($0.0414) per share and revenue of $22.4760 million for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 5:00 PM ET.
LogicBio Therapeutics Stock Performance
Shares of LOGC opened at $9.73 on Tuesday. The stock has a market capitalization of $444.95 million, a P/E ratio of -8.93 and a beta of 2.02. LogicBio Therapeutics has a 12-month low of $7.05 and a 12-month high of $10.35. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.67 and a quick ratio of 1.15. The firm’s 50 day moving average is $9.20 and its 200-day moving average is $8.55.
Institutional Investors Weigh In On LogicBio Therapeutics
An institutional investor recently raised its stake in LogicBio Therapeutics stock. Goldman Sachs Group Inc. increased its stake in LogicBio Therapeutics, Inc. (OTCMKTS:LOGC – Free Report) by 284.9% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 526,673 shares of the company’s stock after acquiring an additional 389,843 shares during the quarter. Goldman Sachs Group Inc. owned approximately 2.00% of LogicBio Therapeutics worth $3,676,000 at the end of the most recent quarter. 46.05% of the stock is currently owned by hedge funds and other institutional investors.
LogicBio Therapeutics Company Profile
LogicBio Therapeutics, Inc, a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia.
Further Reading
- Five stocks we like better than LogicBio Therapeutics
- Tyson Foods Offers a Meaty Opportunity for Income Investors
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
Receive News & Ratings for LogicBio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LogicBio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
